デュプイトレン病市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別（診断、治療）、疾患タイプ別、最終用途別、地域別、競合別、2020-2030F

デュプイトレン病の世界市場規模は、2024年に46億米ドルとなり、2030年までの年間平均成長率（CAGR：Compound Annual Growth Rate）は4.25%で、予測期間中は安定した成長が予測されています。

デュプイトレン病はデュプイトレン拘縮とも呼ばれ、手のひらと指の皮膚の下にある結合組織が侵される進行性の疾患です。19世紀にこの疾患を初めて報告したフランスの外科医ギョーム・デュピュイトレン男爵にちなんで名付けられたこの疾患は、主に指が手のひらの内側に曲がり、機能的な制限をもたらします。

正確な病因は現在も調査中であるが、遺伝的素因が大きな要因であることは広く認められています。家族歴のある人は、この疾患のリスクが著しく高いです。さらに、有病率は北欧やスカンジナビア系の人々で顕著に高いです。その他の危険因子としては、高年齢化、男性（男性の方が6倍近く発症しやすい）、喫煙、飲酒などが挙げられます。

この疾患は、皮膚の下に掌筋膜と呼ばれる肥厚した線維性組織が形成されることが特徴です。時間の経過とともにこの組織は収縮し、指を内側に引き込みます。初期症状として、手のひらに小さなしこりや小結節ができることがあるが、これが紐状の構造に変化し、指の拘縮につながることもあります。この疾患は薬指と小指が最もよく罹患するが、他の指が罹患することもあります。このような拘縮は手の機能を著しく損ない、物を握ったり手を振ったりといった日常的な作業を困難にします。

主要市場促進要因

デュプイトレン拘縮の有病率の上昇

主な市場課題

認知度の低下と診断の遅れ

主要市場動向

患者中心の治療へのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 デュプイトレン病市場展望

• 市場規模・予測
  • 金額別
  • 市場シェア・予測
  • 種類別（診断（身体検査、レントゲン）、治療（手術、放射線療法、針腱膜切開術、ステロイド注射、酵素注射、作業療法、その他））
  • 病気の種類別（I型、II型、III型）
  • 用途別（病院、診療所、学術調査機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のデュプイトレン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のデュプイトレン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のデュプイトレン病市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のデュプイトレン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのデュプイトレン病市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Dupuytren's disease market was valued at USD 4.60 billion in 2024 and is projected to experience steady growth over the forecast period, with a compound annual growth rate (CAGR) of 4.25% through 2030.

Dupuytren's disease, also known as Dupuytren's contracture, is a progressive condition that affects the connective tissue beneath the skin of the palm and fingers. Named after the French surgeon Baron Guillaume Dupuytren, who first described the disease in the 19th century, it primarily causes fingers to bend inward toward the palm, resulting in functional limitations.

While the exact etiology remains unclear despite ongoing research, genetic predisposition is widely acknowledged as a major contributing factor. Individuals with a family history of the condition are at significantly higher risk. Additionally, the prevalence is notably higher among people of Northern European and Scandinavian descent. Other recognized risk factors include advancing age, male gender (with men being nearly six times more likely to develop the condition), smoking, and alcohol consumption.

The disease is characterized by the formation of thickened fibrous tissue-referred to as palmar fascia-beneath the skin. Over time, this tissue contracts, pulling the fingers inward. Initial symptoms may include small lumps or nodules in the palm, which can merge into cord-like structures that lead to finger contractures. The condition most commonly affects the ring and little fingers but may involve other digits as well. These contractures can significantly impair hand function, making routine tasks such as gripping objects or shaking hands challenging.

Key Market Drivers

Rising Prevalence of Dupuytren's Contracture

A significant factor fueling the market's growth is the increasing global prevalence of Dupuytren's contracture. The condition affects approximately 4% of the global population, with disproportionately higher incidence rates in Northern European populations. The male-to-female ratio stands at 5.9:1, indicating a marked gender disparity.

As the number of diagnosed cases continues to rise, so does the demand for diagnostic solutions, therapeutic options, and patient care services. Incidence increases with age, with a majority of cases occurring in individuals over the age of 50. The condition affects both hands in nearly 45% of patients, with unilateral cases more commonly involving the right hand.

As global life expectancy increases-particularly in developed markets such as North America and Europe-a growing segment of the population becomes susceptible to the disease, thereby expanding the potential patient pool. This demographic trend is expected to sustain demand for accessible and effective treatment options.

Dupuytren's contracture is significantly more prevalent among individuals of Northern European descent, with prevalence rates ranging from 4% to 39% in certain populations. Genetic predisposition further elevates the risk, particularly for individuals with a family history of the disease. As awareness of hereditary risk factors improves, early diagnosis and proactive treatment-seeking behaviors are expected to grow, contributing to market expansion.

Historically, underdiagnosis and low awareness among patients and healthcare providers have hindered treatment efforts. However, recent advancements in education, awareness campaigns, and diagnostic technologies have led to increased recognition and more timely diagnoses.

Key Market Challenges

Limited Awareness and Delayed Diagnosis

Despite the increasing prevalence of Dupuytren's disease, limited public and clinical awareness continues to pose a challenge. Early symptoms are often mistaken for normal signs of aging or benign discomfort, leading to delayed diagnosis and missed opportunities for early intervention.

Healthcare providers play a pivotal role in improving early detection, but the relative rarity of the condition and the absence of standardized diagnostic criteria can hinder accurate recognition. Addressing this challenge requires targeted educational initiatives aimed at both medical professionals and the public to raise awareness of risk factors, symptoms, and treatment options.

Key Market Trends

Shift Toward Patient-Centric Care

The healthcare sector is undergoing a notable transformation toward patient-centric models of care, where patients play an active role in managing their treatment pathways. This shift is particularly pertinent to conditions like Dupuytren's disease, where treatment outcomes directly influence quality of life.

As patients become more informed and engaged, there is a growing demand for treatment options that align with individual lifestyles, preferences, and goals. This evolving expectation is encouraging the development of a broader spectrum of therapeutic interventions, emphasizing personalization and improved patient experience.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC.

Report Scope:

In this report, the Global Dupuytren's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dupuytren's Disease Market, By Type:

• Diagnosis {Physical Examination, X-ray}
• Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others}

Dupuytren's Disease Market, By Disease Type:

• Type I
• Type II
• Type III

Dupuytren's Disease Market, By End-use:

• Hospitals
• Clinics
• Academic & Research Institute
• Others

Dupuytren's Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dupuytren's Disease Market.

Available Customizations:

Global Dupuytren's Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Dupuytren's Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
  • 5.1.2. Market Share & Forecast
  • 5.1.3. By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others))
  • 5.1.4. By Disease Type (Type I, Type II, Type III)
  • 5.1.5. By End-use (Hospitals, Clinics, Academic & Research Institute, Others)
  • 5.1.6. By Company (2024)
  • 5.1.7. By Region
• 5.2. Market Map

6. North America Dupuytren's Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Type
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dupuytren's Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Mexico Dupuytren's Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Canada Dupuytren's Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By End-Use

7. Europe Dupuytren's Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Type
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Dupuytren's Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By End-Use
  • 7.3.2. Germany Dupuytren's Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom Dupuytren's Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy Dupuytren's Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain Dupuytren's Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By End-Use

8. Asia-Pacific Dupuytren's Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Type
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Dupuytren's Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India Dupuytren's Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By End-Use
  • 8.3.3. South Korea Dupuytren's Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By End-Use
  • 8.3.4. Japan Dupuytren's Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia Dupuytren's Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By End-Use

9. South America Dupuytren's Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Type
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Dupuytren's Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By End-Use
  • 9.3.2. Argentina Dupuytren's Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By End-Use
  • 9.3.3. Colombia Dupuytren's Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By End-Use

10. Middle East and Africa Dupuytren's Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Type
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Dupuytren's Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Saudi Arabia Dupuytren's Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By End-Use
  • 10.3.3. UAE Dupuytren's Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Nantong Jinghua Pharmaceutical Co., Ltd
• 15.5. Actiza Pharmaceutical Private Limited
• 15.6. Endo International plc
• 15.7. Spear Pharmaceuticals
• 15.8. Hikma Pharmaceuticals PLC
• 15.9. Bristol-Myers Squibb
• 15.10. Glaxosmithkline PLC

16. Strategic Recommendations

17. About Us & Disclaimer